Systemic mastocytosis and bone involvement in a cohort of 75 patients

Annals of the Rheumatic Diseases

Volumn 69, Issue 10, 2010, Pages 1838-1841

  Barete, Stéphane ^a,b,c   Assous, N ^a   De Gennes, C ^a   Grandpeix, C ^c   Feger, F ^b   Palmerini, F ^d   Dubreuil, P ^d   Arock, M ^a   Roux, C ^e   Launay, J M ^c,e   Fraitag, S ^c,e   Canioni, D ^c,e   Billemont, B ^f   Suarez, F ^e   Lanternier, F ^c,e   Lortholary, O ^c,e   Hermine, O ^b,c,e   Frances C ^a,c  

^a SORBONNE UNIVERSITÉ   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c Institut Necker   (France)

^d INSTITUT PAOLI CALMETTES   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f Biochemical Department Université Pierre et Marie Curie Pitié Salpêtrière Hospital ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BONE ATROPHY; BONE DENSITY; BONE RADIOGRAPHY; CYTOREDUCTIVE SURGERY; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL PAIN; OSTEOPENIA; OSTEOPOROSIS; OSTEOSCLEROSIS; PRIORITY JOURNAL; RECURRENT DISEASE; SYSTEMIC MASTOCYTOSIS; VERTEBRA FRACTURE; ADOLESCENT; COMPLICATION; DRUG EFFECTS; FOLLOW UP; LUMBAR VERTEBRA; MIDDLE AGED; PATHOPHYSIOLOGY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUMBAR VERTEBRAE; MALE; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; OSTEOPOROSIS; YOUNG ADULT;

EID: 77957273825     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.124511     Document Type: Article

References (22)

1. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001;25:603-25.
2. Travis WD, Li CY, Bergstralh EJ, et al. Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine (Baltimore) 1988;67:345-68.
3. Andrew SM, Freemont AJ. Skeletal mastocytosis. J Clin Pathol 1993;46:1033-5.
4. Armingaud P, Zerkak D, Lespessailles E, et al. Bone evaluation in ten adults with cutaneous mastocytosis. Ann Dermatol Venereol 2002;129:170-2.
5. Golkar L, Bernhard JD. Mastocytosis. Lancet 1997;349:1379-85.
6. Grardel B, Hardouin P. Mastocytosis and bone manifestations. Results of the survey of the bone and phosphorus-calcium metabolism section of the French Society of Rheumatology. Rev Rhum Mal Osteoartic 1992;59:57-63.
7. Grieser T, Minne HW. Systemic mastocytosis and skeletal lesions. Lancet 1997;350:1103-4.
8. Harvey JA, Anderson HC, Borek D, et al. Osteoporosis associated with mastocytosis confined to bone: report of two cases. Bone 1989;10:237-41. (Pubitemid 20029896)
9. Lidor C, Frisch B, Gazit D, et al. Osteoporosis as the sole presentation of bone marrow mastocytosis. J Bone Miner Res 1990;5:871-6.
10. Brumsen C, Hamdy NA, Papapoulos SE. Osteoporosis and bone marrow mastocytosis: dissociation of skeletal responses and mast cell activity during long-term bisphosphonate therapy. J Bone Miner Res 2002;17:567-9.
11. Cundy T, Beneton MN, Darby AJ, et al. Osteopenia in systemic mastocytosis: natural history and responses to treatment with inhibitors of bone resorption. Bone 1987;8:149-55. (Pubitemid 17111857)
12. Lim AY, Ostor AJ, Love S, et al. Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment. Ann Rheum Dis 2005;64:965-6.
13. Marshall A, Kavanagh RT, Crisp AJ. The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis. Br J Rheumatol 1997;36:393-6. (Pubitemid 127457231)
14. Horny HP, Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 2001;25:543-51.
15. Schwartz LB. Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders. Leuk Res 2001;25:553-62.
16. Lanternier F, Cohen-Akenine A, Palmerini F, et al. Phenotypic and genotypic characteristics of mastocytosis according to the age of onset. PLoS ONE 2008;3:e1906.
17. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994;4:368-81.
18. Johansson C, Roupe G, Lindstedt G, et al. Bone density, bone markers and bone radiological features in mastocytosis. Age Ageing 1996;25:1-7. (Pubitemid 26036220)
19. Rizzoli R, Greenspan SL, Bone G III, et al. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002;17:1988-96.
20. Laroche M, Bret J, Brouchet A, et al. Clinical and densitometric efficacy of the association of interferon alpha and pamidronate in the treatment of osteoporosis in patients with systemic mastocytosis. Clin Rheumatol 2007;26:242-3.
21. Lehmann T, Beyeler C, Lämmle B, et al. Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-2B. Br J Rheumatol 1996;35:898-900.
22. Kushnir-Sukhov NM, Brittain E, Reynolds JC, et al. Elevated tryptase levels are associated with greater bone density in a cohort of patients with mastocytosis. Int Arch Allergy Immunol 2006;139:265-70. (Pubitemid 43289511)